Gvh-499

(also referred to as ) is an investigational HIV-1 capsid inhibitor currently in clinical development as a long-acting antiretroviral agent. It is being studied as part of a potential "ultra-long-acting" (ULA) treatment regimen. Key Development Details (as of early 2026) Mechanism of Action